THE EVIDENCE
The Issue
What happened, who was harmed, and why it matters now. An overview of the drug trials, the scale of the harm, and what the Royal Commission did and did not address.
Between 1998 and 2002, approximately 3,000 members of the Australian Defence Force were administered mefloquine and tafenoquine during deployments to East Timor and Bougainville. In significant part, these were formal clinical drug trials. Both drugs are now recognised by regulatory agencies in Australia, the United States, and Europe as carrying substantial neuropsychiatric risk — including effects that may persist permanently.
The harms documented among affected veterans include paranoia, dissociation, psychosis, personality change, and suicide. They also include domestic violence. This site documents what that meant for the people who were not on deployment: the partners who came home to someone changed, and the children who grew up without an explanation.
All pages on this site are accessible through the directory below. Each section is self-contained and can be read independently. The site distinguishes throughout between established fact, plausible mechanism, documented case evidence, and areas of genuine uncertainty. These registers are defined in full in About This Report and in the Glossary.